GEN-MKT-18-7897-A
Jul 26, 2016 | Blogs, Environmental / Industrial | 0 comments
The United States Environmental Protection Agency (EPA), under the 1996 Safe Drinking Water Act (SDWA), requires a new list of no more than 30 unregulated contaminants to be monitored by public drinking water systems. Known as the Unregulated Contaminant Monitoring Rule (UCMR), a new list is published every five years. The last rule, UCMR3, was published May 2, 2012, and is the focus of the following application note, “Analysis of Perfluoroalkyl (PFFA) Acids Specified under the UCMR3 Using the QTRAP® 6500 LC-MS/MS system,” which can be found in the Food and Environmental Compendium.
OverviewUsing the guidelines laid out by EPA Method 537, “A Determination of Selected Perfluoroalkyl Acids in Drinking Water by Solid Phase Extraction and Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS),” this application note describes the performance of the QTRAP 6500. Within the scope of EPA 537, there are 14 PFAAs. Six are specified under the UCMR3 monitoring list.
ProcessSample preparation and data processing were carried out according to EPA Method 537 without deviation unless specifically noted. The analysis was carried out using the QTRAP 6500 coupled with the Agilent 1260 HPLC with an Eksigent ULC 100 HTC-xt autosampler. Quantitation using MultiQuant ™ 3.0.
ConclusionThe lower the detection, the harder the QTRAP 6500 works for you as it easily meets the UCMR3 reporting limits. See what more it can do when you download the compendium. Download the compendium >
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network